Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 08, 2025 16:05 ET | Source: Entera Bio Ltd.

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates

FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis...